Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10000852 | International Journal of Oral and Maxillofacial Surgery | 2005 | 6 Pages |
Abstract
Peroxiredoxin (Prx) I is an antioxidant protein expressed in proliferating cells. We investigated Prx I as marker for tongue cancer status by correlating clinical features with Prx I expression. Samples from 132 patients with squamous cell carcinoma in the tongue were examined by immunohistochemistry with an anti-Prx I antibody. Correlations between Prx I expression and the clinical features of tumors were statistically determined using univariate and multivariate analyses. Univariate analysis showed Prx I was significantly associated with local recurrence (PÂ =Â 0.033). By multiple logistic regression analysis, Prx I expression was associated with local recurrence (odds ratio: 2.84; 95% confidence interval: 1.09-7.43; PÂ =Â 0.034) and lymph node recurrence (odds ratio: 2.86; 95% confidence interval: 1.02-8.01; PÂ =Â 0.046). Our results suggested that Prx I expression indicates tumors with a high potential for recurrence. Prx I may be used clinically to guide treatment for squamous cell carcinoma of the tongue.
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
T. Yanagawa, K. Omura, H. Harada, T. Ishii, J. Uwayama, K. Nakaso, S. Iwasa, Y. Koyama, K. Onizawa, H. Yusa, H. Yoshida,